Streetbeat News

Earnings

ACLX

Arcellx (NASDAQ:ACLX) reported Q2 losses of $(0.50) per share, missing the analyst consensus estimate of $(0.31) by 61.29%. The company also reported quarterly sales of $14.30 million, missing the analyst consensus estimate of $40.55 million by 64.73%.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2023 | 8:38 pm

RVPH

Reviva Pharmaceuticals reported Q2 losses of $(0.55) per share, missing the analyst consensus estimate of $(0.28) by 96.43%. This represents a 89.66% increase in losses compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2023 | 8:38 pm

OXAC

Oxbridge Acquisition Corp. reported Q2 earnings per share (EPS) of $(0.01), a decrease from $0.01 year-over-year (YoY). The company's revenue increased to $691K from $503K YoY.

Portfolio Pulse from Happy Mohamed

August 14, 2023 | 8:36 pm

PSTV

Plus Therapeutics reported Q2 losses of $(0.59) per share, beating the analyst consensus estimate of $(1.91) by 69.11%. This is an 83.61% increase over losses from the same period last year. The company also reported quarterly sales of $1.85 million, beating the analyst consensus estimate of $790.00 thousand by 134.68%.

Portfolio Pulse from mahesh@benzinga.com

August 14, 2023 | 8:36 pm

DMS

Digital Media Solutions (DMS) has projected its Q3 net revenue to be between $70M-$72M, which is significantly lower than the consensus estimate of $93.76M.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2023 | 8:36 pm

GETY

Getty Images Holdings (NYSE:GETY) reported Q2 earnings per share of $(0.01), missing the analyst consensus estimate of $0.04 by 125 percent. This is a 103.45 percent decrease from the same period last year. The company also reported quarterly sales of $225.68 million, missing the analyst consensus estimate of $235.64 million by 4.23 percent, a 3.28 percent decrease from the same period last year.

Portfolio Pulse from bharat@benzinga.com

August 14, 2023 | 8:36 pm

FSI

Flexible Solutions Intl (FSI) reported Q2 earnings of $0.07 per share, missing the analyst consensus estimate of $0.09 by 22.22%. This is a 46.15% decrease from the same period last year. The company also reported quarterly sales of $10.33 million, missing the analyst consensus estimate of $12.99 million by 20.47%. This is a 7.47% decrease from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2023 | 8:35 pm

XWEL

XWELL reported Q2 sales of $8.20 million, beating the analyst consensus estimate of $8.15 million by 0.61 percent. However, this represents a 39.69 percent decrease compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2023 | 8:34 pm

DSGN

Design Therapeutics (NASDAQ:DSGN) reported Q2 losses of $(0.36) per share, beating the analyst consensus estimate of $(0.40) by 10 percent. However, this represents a 33.33 percent increase in losses compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2023 | 8:34 pm

FBRX

Forte Biosciences (NASDAQ:FBRX) reported a 100% increase in its Q2 losses year-over-year, with losses of $(0.42) per share compared to $(0.21) per share in the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2023 | 8:33 pm